Physician profile
Amy Le
NPI 1699262899
$467.24
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $149 · 2024: $318.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $467.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $467.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $116.02 | 2023-2024 | Imfinzi, Tagrisso |
| Daiichi Sankyo INC. | $53.82 | 2024 | Enhertu |
| Jazz Pharmaceuticals INC. | $52.25 | 2023-2024 | |
| Merck Sharp & Dohme LLC | $50.79 | 2023-2024 | Keytruda, Lynparza, Welireg |
| Takeda Pharmaceuticals U.S.A., INC. | $46.13 | 2024 | Hyqvia, Fruzaqla |
| Taiho Oncology, INC. | $35.81 | 2023 | |
| Rigel Pharmaceuticals, INC. | $23.77 | 2024 | Rezlidhia, Tavalisse |
| Deciphera Pharmaceuticals INC. | $20.82 | 2023 | Qinlock |
| Lilly USA, LLC | $20.35 | 2024 | Jaypirca, Verzenio |
| Incyte Corporation | $18.23 | 2023 | Jakafi |
| Myriad Genetic Laboratories, INC. | $16.19 | 2024 | Prolaris |
| Mirati Therapeutics, INC. | $13.06 | 2023 | Krazati |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Le listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.